ReviewHerz2018
Treatment options in myocarditis and inflammatory cardiomyopathy : Focus on i. v. immunoglobulins.
Review in Herz, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Brazilian Society of Cardiology Guideline on Myocarditis - 2022.Arquivos brasileiros de cardiologia · 2022Guideline
- Corticosteroids and Intravenous Immunoglobulin in Pediatric Myocarditis: A Meta-Analysis.Frontiers in pediatrics · 2019Pooled it
- Cardiogenic Shock Management in the Modern Era: A Narrative Review of Percutaneous Mechanical Circulatory Support Devices.Journal of cardiovascular development and disease · 2025Review
- Revitalizing Colchicine: Novel Delivery Platforms and Derivatives to Expand Its Therapeutic Potential.International journal of molecular sciences · 2025Review
- Viral Myocarditis.The Yale journal of biology and medicine · 2024Review
- A retrospective analysis of clinical characteristics and outcomes of pediatric fulminant myocarditis.BMC pediatrics · 2024Article
- Analysis of clinical features of heart failure in children with cardiomyopathy and improved ejection fraction.Translational pediatrics · 2024Article
- Multifunctional nanoparticle-mediated combining therapy for human diseases.Signal transduction and targeted therapy · 2024Review
- Global burden of myocarditis and cardiomyopathy in children and prediction for 2035 based on the global burden of disease study 2019.Frontiers in cardiovascular medicine · 2023Article
- COVID-19 Related Myocarditis in Adults: A Systematic Review of Case Reports.Journal of clinical medicine · 2022Review
- First Case of Acute Myocarditis Caused by Metapneumovirus in an Immunocompromised 14-year-old Girl.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2022Article
- Article
- Cardiovascular Abnormalities in Juvenile Dermatomyositis: A Scoping Review for the Clinical Rheumatologists.Frontiers in medicine · 2022Article
- Review
- Contemporary approach to understand and manage COVID-19-related arrhythmia.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2021Review
- Targeted treatment in viral-associated inflammatory cardiomyopathy.Clinical case reports · 2021Article
- Letter regarding the article "Immunomodulatory treatment for lymphocytic myocarditis-a systematic review and meta-analysis".Heart failure reviews · 2021Article
- Anti-mitochondrial Antibodies in Patients with Dilated Cardiomyopathy.Internal medicine (Tokyo, Japan) · 2021Article
- Effect of gamma globulin combined with creatine phosphate on viral myocarditis.American journal of translational research · 2021Article
- Fulminant myocarditis: a comprehensive review from etiology to treatments and outcomes.Signal transduction and targeted therapy · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For myocarditis and inflammatory cardiomyopathy, an etiologically driven treatment is today the best option beyond heart failure therapy. Prerequisites for this are noninvasive and invasive biomarkers including endomyocardial biopsy and polymerase chain reaction on cardiotropic agents. Imaging by Doppler echocardiography and cardiac magnetic resonance imaging as well as cardiac biomarkers such as C‑reactive protein, N‑terminal pro-B-type natriuretic peptide , and troponins can contribute to the clinical work-up of the syndrome but not toward elucidating the underlying cause or pathogenetic process. This review summarizes the phases and clinical features of myocarditis and gives an up-to-date short overview of the current treatment options starting with heart failure and antiarrhythmic therapy. Although inflammation in myocardial disease can resolve spontaneously, often specific treatment directed against the causative agent is required. For fulminant, acute, and chronic autoreactive myocarditis, immunosuppressive treatment has proven to be beneficial in the TIMIC and ESETCID trials; for viral cardiomyopathy and myocarditis, intravenous immunoglobulin IgG subtype and polyvalent intravenous immunoglobulins IgG, IgA, and IgM can frequently resolve inflammation. However, despite the elimination of inflammation, the eradication of parvovirus B19 and human herpesvirus-6 is still a challenge, for which ivIg treatment can become a future key player.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.